VTRS vs. TAK, ALNY, TEVA, GMAB, RPRX, BGNE, BMRN, UTHR, RDY, and SRPT
Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.
Viatris (NASDAQ:VTRS) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.
Viatris presently has a consensus price target of $11.00, suggesting a potential upside of 3.77%. Takeda Pharmaceutical has a consensus price target of $14.00, suggesting a potential upside of 4.87%. Given Takeda Pharmaceutical's higher probable upside, analysts plainly believe Takeda Pharmaceutical is more favorable than Viatris.
79.9% of Viatris shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Takeda Pharmaceutical received 79 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 56.82% of users gave Takeda Pharmaceutical an outperform vote while only 35.59% of users gave Viatris an outperform vote.
Viatris has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.
Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 4.5%. Takeda Pharmaceutical pays an annual dividend of $0.26 per share and has a dividend yield of 1.9%. Viatris pays out -800.0% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 47.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.
Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Takeda Pharmaceutical has a net margin of 6.18% compared to Viatris' net margin of -0.37%. Viatris' return on equity of 16.63% beat Takeda Pharmaceutical's return on equity.
In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 5 mentions for Viatris. Takeda Pharmaceutical's average media sentiment score of 0.27 beat Viatris' score of 0.26 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.
Summary
Takeda Pharmaceutical beats Viatris on 11 of the 18 factors compared between the two stocks.
Get Viatris News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
